After Prometheus sale, Mark McKenna heads to another autoimmune biotech as chair of Apogee

After Mark McKenna sold a biotech for $10.8 billion, the executive recruiters likely came knocking, trying to poach the CEO who took an immunology and inflammation biotech from early-stage private financing to an IPO to key Phase II data in the span of four years.

As it was, two months…
Click here to view original post